Literature DB >> 1677997

Induction of tumour hypoxia by FAA and TNF: interaction with bioreductive drugs.

H S Edwards1, J C Bremner, I J Stratford.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1677997     DOI: 10.1080/09553009114552181

Source DB:  PubMed          Journal:  Int J Radiat Biol        ISSN: 0955-3002            Impact factor:   2.694


× No keyword cloud information.
  6 in total

1.  Antivascular approaches to solid tumour therapy: evaluation of tubulin binding agents.

Authors:  D J Chaplin; G R Pettit; C S Parkins; S A Hill
Journal:  Br J Cancer Suppl       Date:  1996-07

Review 2.  Assessing the bioreductive effectiveness of the nitroimidazole RSU1069 and its prodrug RB6145: with particular reference to in vivo methods of evaluation.

Authors:  J C Bremner
Journal:  Cancer Metastasis Rev       Date:  1993-06       Impact factor: 9.264

Review 3.  Bioreducible mustards: a paradigm for hypoxia-selective prodrugs of diffusible cytotoxins (HPDCs).

Authors:  W A Denny; W R Wilson
Journal:  Cancer Metastasis Rev       Date:  1993-06       Impact factor: 9.264

4.  The effect of pH on the aerobic and hypoxic cytotoxicity of SR4233 in HT-29 cells.

Authors:  L D Skarsgard; M W Skwarchuk; A Vinczan; D J Chaplin
Journal:  Br J Cancer       Date:  1993-10       Impact factor: 7.640

5.  Increasing the effect of photodynamic therapy on the RIF-1 murine sarcoma, using the bioreductive drugs RSU1069 and RB6145.

Authors:  J C Bremner; G E Adams; J K Pearson; J M Sansom; I J Stratford; J Bedwell; S G Bown; A J MacRobert; D Phillips
Journal:  Br J Cancer       Date:  1992-12       Impact factor: 7.640

6.  Enhancement of the anti-tumour effects of the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) by combination with 5-hydroxytryptamine and bioreductive drugs.

Authors:  C J Lash; A E Li; M Rutland; B C Baguley; L J Zwi; W R Wilson
Journal:  Br J Cancer       Date:  1998-08       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.